This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
OptiNose Inc. (ENT/allergy therapeutics) raised $37mm in a Series D round led by new backer Fidelity Management & Research Co. Returning investors Avista Capital Partners, Entrepreneurs Fund, and others also participated. Earlier this year the company filed an NDA for OPN375 (fluticasone propionate), a glucocorticoid receptor for nasal polyposis; FDA approval is expected in Q3 2017. OptiNose will use proceeds from this offering to support OPN375's anticipated 2018 commercial launch. The company has raised $129.1mm to date.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?